Pavmed Inc. (NSDQ:PAVM) said today that it closed its offer to exchange two Series W warrants for a single Z warrant. Approximately 10,151,682 Series W warrants were tendered and not withdrawn, which represents 96.4% of outstanding Series W warrants, the New York-based company said. Get the full story at our sister site, Drug Delivery Business News.
Pavmed reports prelim results of warrant exchange offer
Pavmed Inc. (NSDQ:PAVM) today reported the preliminary results of its offer to exchange two Series W warrants for a single Z warrant. Approximately 10,151,682 Series W warrants were tendered and not withdrawn, which represents 96.4% of outstanding Series W warrants, the New York-based company said. Get the full story at our sister site, Drug Delivery Business News. […]
Intersect ENT launches Sinuva steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) launched its steroid-releasing sinus implant, Sinuva, in the U.S. today. The company’s drug-eluting device is designed to treat nasal polyp disease in patients who have undergone previous sinus surgery. Sinuva is placed during a routine doctor’s office visit and releases an anti-inflammatory steroid, mometasone furoate, directly to the patient’s nasal polyps for up to […]
Cochlear donates $10m to Johns Hopkins for new hearing loss center, research
Cochlear Ltd. (ASX:COH) said today it donated $10 million to the Johns Hopkins Bloomberg School of Public Health to found the Cochlear Center for Hearing and Public Health, which it touted as the first academic institute looking to address hearing loss as a global health priority. The new center is slated to be led by […]
Stryker closes $664m Entellus Medical buy
Entellus Medical (NSDQ:ENTL) said today it closed its $664 million sale to Stryker (NYSE:SYK), becoming a wholly owned subsidiary of the Kalamazoo, Mich.-based medtech firm. Plymouth, Minn.-based Entellus, founded in 2006, makes a family of minimally invasive balloon device products, including its flagship Xpress device, that are designed to treat blocked sinuses. Earlier this year it closed the […]
Entellus Medical shareholders approve $662m Stryker buyout
Entellus Medical (NSDQ:ENTL) shareholders yesterday approved the $662 million cash merger offer from Stryker (NYSE:SYK). Plymouth, Minn.-based Entellus, founded in 2006, makes a family of minimally invasive balloon device products, including its flagship Xpress device, that are designed to treat blocked sinuses. Earlier this year it closed the $81 million buyout of Spirox and its Latera absorbable nasal […]
Frequency touts first-in-human safety study for hearing loss therapy
Frequency Therapeutics has finished a first-in-human study of its progenitor cell activation therapy, FX-322, in nine adults with severe to profound sensorineural hearing loss. The company’s candidate is a combination of small molecules that are designed to activate progenitor cells and trigger the formation of new hair cells in the inner ear. Get the full story […]
Advanced Bionics to connect cochlear implants to cell phones, TVs using Sonova’s chip tech
Advanced Bionics said today that it plans to integrate Sonova‘s Sword chip and wireless radio tech into its sound processors. Sonova’s technology can connect hearing devices to almost any kind of cell phone, the company explained, without the need for an extra streaming device. “By offering a solution to the entire market – including the […]
Sensorion, Cochlear collab to study combo therapies for patients with cochlear implants
Sensorion, a biotech working on therapies for inner ear diseases, said today that it inked a deal with Cochlear Ltd (ASX:COH) to study combination therapies for patients with cochlear implants. According to the deal, the companies will combine Sensorion’s SENS-401 compound with cochlear implants in preclinical studies starting next year. The drug-device therapies could be in clinical […]
Intersect ENT wins FDA nod for Sinuva polyp-disease-treating sinus implant
Intersect ENT (NSDQ:XENT) said today it won FDA approval for its Sinuva mometasone furoate sinus implant designed to treat recurrent nasal polyp disease in patients who have previously had ethmoid sinus surgery. The Sinuva device is designed to be implanted during a routine physician office visit and expands into the sinus cavity to deliver an anti-inflammatory steroid […]
Stryker pledges $662m cash for Entellus Medical
Entellus Medical (NSDQ:ENTL) said today that it struck a deal to be acquired by Stryker (NYSE:SYK) for $662 million in cash. Plymouth, Minn.-based Entellus, founded in 2006, makes a family of minimally invasive balloon device products, including its flagship Xpress device, that are designed to treat blocked sinuses. Earlier this year it closed the $81 million […]
- 1
- 2
- 3
- …
- 10
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+